Wu-Tang Has Message for Shkreli, Via a Song
'Lesson Learn'd' will be on group's new album coming out Oct. 13
By Jenn Gidman,  Newser Staff
Posted Sep 22, 2017 1:58 PM CDT
Raekwon, left, and RZA from the hip-hop group the Wu-Tang Clan perform at the Governors Ball Music Festival on June 3, 2017, in New York.   (Photo by Charles Sykes/Invision/AP)

(Newser) – Martin Shkreli may have once boasted the "rarest album ever created," but not everyone's impressed—most notably, the guys behind that coveted list of tracks. And to show their distaste for "Pharma Bro," Wu-Tang Clan has dedicated a brand-new track on its new Wu-Tang: The Saga Continues album, coming out Oct. 13, the Guardian reports. "Lesson Learn'd" made its way onto SoundCloud Friday, a three-minute-plus song that reveals a brief Clan diss toward Shkreli and his much-maligned actions during his tenure as the price-gouging head of his pharmaceuticals company: "Hater/Wouldn't last a day in my shoes/You know very well/Bet he swell/You can tell he jeal'/My price hikin' like the pills Martin Shkreli sell." It's not the first time words have been exchanged between Wu-Tang members and Shkreli, who recently is said to have sold the group's rare Once Upon a Time in Shaolin album for more than $1 million on eBay.

Per the New York Daily News, Ghostface Killah and Shkreli got into it on social media in early 2016, culminating with an epic, nearly 12-minute-long video rant in which Ghostface called Shkreli a "fake-ass super villain" and "PeeWee Shkreli," among other names. And now, the "rare" Wu-Tang album Shkreli is said to have hawked online may not be the deal he thought it would be: Some are saying it may not be an authorized Wu-Tang album, while UPROXX notes that other issues are holding up the deal even if it is a legit album, including Shkreli's return behind bars after threatening Hillary Clinton and whispers that the winning bidder may have been in cahoots with Shkreli to drive the price of the auction up.

My Take on This Story
Show results without voting  |  
32%
4%
4%
37%
1%
23%